<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81961">
  <stage>Registered</stage>
  <submitdate>12/04/2007</submitdate>
  <approvaldate>30/04/2007</approvaldate>
  <actrnumber>ACTRN12607000225415</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of  intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy</studytitle>
    <scientifictitle>Efficacy of  intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic macular edema in severe non proliferative diabetic retinopathy (NPDR)or proliferative diabetic retinopathy(PDR)</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with Severe NPDR or PDR who need panretinal photocoagulation(PRP) and have macular edema with same stage in both eyes are randomized to two groups. One eye is in the injection group The other eye is active control. in the first group 4 mg triamcinolone acetonide is injected intravitreally 1 week before first session of PRP . PRP is done in 3 sessions 1 week apart.</interventions>
    <comparator> In the active control group just PRP is done. PRP is done in 3 sessions 1 week apart.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>10 letter improvement of visual acuity on Early Treatment Diabetic Retinopathy Study (ETDRS) chart</outcome>
      <timepoint>At baseline and at 1 month and 6 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes of central macular thickness (CMT) in OCT (optical coherence tomography).</outcome>
      <timepoint>At baseline and at 1 month and 6 month.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All diabetic patients with severe NPDR or PDR and same stage macular edema in both eyes (Have or not have CSME in both eyes).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Tractional retinal detachment, glaucoma, corticosteroid responders, active ocular surface disease, media opacity precluding visibility of fundus details.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>assessor and data analyst are blind</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/11/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Eye Research Center, Farabi Eye Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran University of medical sciences</fundingname>
      <fundingaddress />
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Purpose was to evaluate efficacy of  intravitreal triamcinolone acetonide before pan retinal photocoagulation for improvement of visual acuity and macular edema in diabetic retinopathy. Our hypothesis is that triamcinolone acetonide before PRP helps for decreasing macular edema and improvement of visual acuity</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review of Board (IRB)and Ethics committee of Tehran University of Medical Sciences</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/10/2005</ethicapprovaldate>
      <hrec>356</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hamideh Shenazandi</name>
      <address>Farabi Eye Hospital
Qazvin Square
Tehran </address>
      <phone>+98 21 55410006-9</phone>
      <fax>+98 21 55421002</fax>
      <email>shenazandi@razi.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Hamideh Shenazandi</name>
      <address>Farabi Eye Hospital
Qazvin Square
Tehran</address>
      <phone>+98 21 55410006-9</phone>
      <fax>+98 21 55421002</fax>
      <email>shenazandi@razi.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>